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Background: The 9p21.3 locus is strongly associated with the risk of coronary artery disease (CAD) and with type 2
diabetes (T2D). We investigated the association of 9p21.3 variants with severity of CAD (defined by the number of
vessel diseased [VD]) in the presence and absence of T2D.
Methods: We tested 11 9p21.3-variants for association in a white Italian study (N = 2,908), and carried out
replication in 2 independent white populations, a German study (N = 2,028) and a Canadian Study (N=950). SNP
association and permutation analyses were conducted.
Results: We identified two 9p21.3-variants, rs4977574 (P < 4×10-4) and rs2383207 (P < 1.5×10-3) that were
associated with severity of CAD in subjects without T2D. Association of rs4977574 with severity of CAD was
confirmed in the Canadian Study. Results from subgroup analysis among patients with T2D showed an interaction
between rs10738610 and T2D with P = 4.82×10-2. Further investigation showed that rs10738610 (P < 1.99×10-2) was
found to be significantly associated with severity of CAD in subjects with T2D.
Conclusions: The 9p21.3 locus is significantly associated with severity of CAD. The number of associations of
9p21.3 variants with severity of CAD is variable to the presence and absence of T2D. In a CAD-susceptible region of
115 kb, there is only one variant associated with the severity of coronary vessel disease in the presence of type 2
diabetes.
Keywords: Severity of CAD, Coronary artery disease, Diabetes mellitus, T2D, 9p21.3, Genetics, Single nucleotide
polymorphismBackground
Coronary artery disease (CAD) concomitant with type 2
diabetes (T2D) is the leading cause of cardiovascular
(CV) morbidity and mortality. Severity of CAD is higher
in diabetics than in non-diabetics, often presenting itself
as a 3-vessel disease with a more diffuse coronary artery
involvement. Thus, diabetics have higher risks for com-
plications frequently leading to death [1].* Correspondence: natalia.rivera@guest.unimi.it
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reproduction in any medium, provided the orThe combination of genetics, intermediate phenotypes,
and environmental factors (such life-style) play a major
role in the pathogenesis of CAD and T2D, including de-
termining the conditions and stability of these diseases.
The genetic architectures of CAD and T2D are dependent
on multiple genetic and environmental triggers that may
overlap or may be specific to each disease. The estimated
heritability of CAD ranges from 30 to 60% [2,3], whereas
of T2D is from 40 to 90% [4,5].
To date, the 9p21.3 locus is the most consistently repli-
cated genetic locus for CAD [6-11] and T2D [12-14].
The association with this locus is independent oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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smoking, hypertension, and hyperlipidemia. Moreover, the
9p21.3 locus is phenotypically heterogeneous, since it is
also associated with various phenotypes, including myo-
cardial infarction [15], arterial stiffness [16], aortic
aneurysm [17], ischemic stroke [18,19], glioma [20], and
malignant melanoma [21]. The role of the susceptible re-
gion for CAD and T2D at the 9p21.3 locus, a region
located on two adjacent haplotype blocks, a 44-kb (from
rs10116277 to rs1333049) and a 4-kb block (from
rs10965243 to rs10757283) [22], has been a major ques-
tion of research for determining its implication in the
pathogenesis of these diseases. Clearly, identifying genetic
variants associated with severity of CAD in the presence
and absence of T2D is crucial for understanding to what
extent genetic variations at the 9p21.3 locus interplay in
the pathogenesis of these conditions.
This study was undertaken to investigate the associ-
ation of 9p21.3-variants with severity of CAD in patients
without and with T2D. Thus, first, we sought to identify
whether 9p21.3 variants have a role in determining the
severity of CAD; and second, we assessed the impact of
T2D in the associations with severity of CAD.
Methods
Subjects and phenotype characterization
Participants were of white European ancestry. All studies
had protocols approved by local institutional boards.
Participants provided written consent and gave permis-
sion to use their DNA for research purposes. Baseline
characteristics for all participating studies are presented
in Additional file 1: Table S1. Baseline measures of clin-
ical and demographic characteristics were measured at
each medical facility at the time of the participants’ en-
rollment in the study.
In all participating studies, severity of CAD was defined
according to angiograms showing number of vessels dis-
ease ≥ 1 (namely, 1-vessel, 2-vessel, and 3-vessel disease)
with > 50% lumen diameter stenosis and in accordance
with clinical standards and guidelines for coronary angiog-
raphy. T2D was defined as treatment with insulin or
oral hypoglycemic drugs, or as elevated (> 126 mg/dL
or > 7.0 mmol/L) levels of fasting, non-stressed blood
glucose on at least two separate occasions in conjunc-
tion with adhering to ongoing dietary measures to con-
trol glucose level. Early-onset CAD was defined as
onset ≤ 55 years of age and late-onset CAD as other-
wise. Type 1 diabetics were excluded in all studies.
The Italian study consists of 2,908 subjects (67.2% male)
aged 20 to 90 years diagnosed with and without severity of
CAD. Specifically, 1,696 subjects were recruited from both
the Clinica Mediterranea in Naples and the Multimedica
Hospital in Milan and 1,212 were recruited from the
Campania Salute (CS) Network at the University FedericoII in Naples. Subjects from the Clinica Mediterranea and
the Multimedica Hospital were scheduled for first-time
elective coronary angiography because of clinical suspi-
cion and/or diagnoses of CAD. Herein, an angiogram was
called “normal” (or “unaffected without severity of CAD”)
if it showed number of vessels <1 and smooth lumens
with stenosis < 50%, whereas if it showed otherwise, the
angiogram was called “affected with severity of CAD” and
was further characterized by objective coronary angiog-
raphy and in accordance with the ACC/AHA guidelines
for coronary angiography [23]. Within the 1,696 subjects,
1,541 were “affected with severity of CAD” and 155 were
“unaffected without severity of CAD”. The remaining
1,212 subjects were drawn from the Campania Salute (CS)
Network, an open registry that collects information from
a network of general practitioners and hospitals linked
with a coordinating center (University Federico II in
Naples). These subjects were used as “controls” (or “un-
affected without severity of CAD”) and were selected
based on their medical history and absent diagnosis for
cardiovascular disease predefined by the exclusion criteria
of the open registry study design. Exclusion criteria of the
CS Network included history of previous myocardial in-
farction or angina or procedures of coronary revasculari-
zation, stroke, or transitory ischemic attack, congestive
heart failure, and chronic kidney disease (defined as
GFR < 30 ml/min per 1.73 m2). Additionally, partici-
pants enrolled in the CS network were subjected to an
active follow-up program including periodically cardiac
and carotid ultrasounds aimed to the prevention and
the reduction of cardiovascular events in a population
of hypertensives. Patients who presented signs of pre-
clinical atherosclerosis or CAD were subjected to fur-
ther exams, including coronary angiography. Further
details on the design of the CS Network can be found
elsewhere [24].
Combining all subjects from the three centers, we had
a total sample size of 2,908 participants. Within this co-
hort, 19% of participants were diabetics. Additionally,
15% of patients had early-onset CAD and 31% had late-
onset CAD according to available data records.
The German study included 2,028 subjects (78%
males) aged 27 to 92 years characterized with ischemic
symptoms or evidence of myocardial ischemia in the
presence of 50% de novo stenosis located in native cor-
onary vessels. Specifically, 1,917 patients were “affected
with severity of CAD” and 111 were “unaffected without
severity of CAD”. Severity of vessel disease was recorded
as qualitative morphological lesion conditions by means of
standard criteria. Baseline, post-procedural, and follow-up
angiograms were digitally recorded and assessed off-line in
the quantitative angiographic core laboratory (ISAR Center)
with an automated edge-detection system (CMS version
7.1; MEDIS Imaging Systems, Leiden, the Netherlands) by
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diabetics. Further details of this study are described else-
where [25].
The Canadian study was part of the Ottawa Heart
Genomics Study [26] and consisted of 950 subjects (71%
males) aged < 55 (males) and < 65 (female) with at least
one epicardial stenosis > 50% who were considered as
early onset cases of CAD. All subjects were “affected
with severity of CAD”. The coronary angiograms were
assessed by two independent angiographers blind to the
results of the genotype. For a vessel to be scored, sten-
osis > 50% had to be noted in an epicardial coronary
vessel of interest or in one of its major branches. In the
event of discordance on the number of vessel scored be-
tween two reviewers, angiograms were scored by a third
independent reviewer. Modified Gensini and modified
Duke coronary scores were derived in subjects who were
not previously bypassed. Subjects who had previously
undergone PCI for a lesion for which the degree of sten-
osis was not known were not analyzed. Herein, all sub-
jects were non-diabetics. Exclusion of diabetic patients
was part of the study design and their exclusion criteria
of the Ottawa Heart Genomics Study. Further details of
this study and subject characteristics are described in
detailed elsewhere [27].
Specimen collection, SNP selection, and genotyping
A blood sample was drawn from each participant during
the regular routing examination for coronary artery
angiogram. Genomic DNA was extracted from periph-
eral blood lymphocytes using the DNA Qiamp Midi kit
(QIAGEN Inc. Valencia, CA) and genotyped accordingly.
In the Italian study, 11 SNPs (rs7044859, rs10965215,
rs564398, rs7865618, rs10116277, rs4977574, rs2383207,
rs10738610, rs10757278, rs1333049, rs10811661) were
selected from published genome-wide association studies
(GWAS) of CAD [9,11,15] and T2D [13,14] - that is, 7
SNPs were chosen at P = 1×10-8 and 4 SNPs at P < 1×10-6.
Herein, genotyping was carried out in two stages; in the
first stage 1,696 subjects (from Clinica Mediterranea and
Multimedica Hospital) were genotyped using TaqManW
Pre-Designed SNP Genotyping Assays (Applied Biosys-
tems), whereas in the second stage 1,212 subjects (from
the CS Network) were genotyped with Illumina
Human1M-Duo BeadChip array. In the array, 7 of 11
selected SNPs were present and thus extracted after
quality control filtering, which included minor allele
frequency (MAF) ≤1%, Hardy-Weinberg equilibrium
(HWE) P < 1×10-6, and SNP and subject call rates ≤ 97%.
The missing SNPs (rs10116277, rs10738610, rs10757278,
rs1333049) were imputed with reference to HapMap CEU
release 22 build 36 using the maximum likelihood method
implemented in MACH (version 1.0.15). Further details on
genotyping and imputation are given in Additional file 1:Table S3. Genotypes of Italian participants were pooled to-
gether, resulting in 2,908 subjects and 11 SNPs to analyze.
In the replication stage: in the German study, SNP
rs1333049 was available for replication and selection for
studying the severity of CAD. Genotyping of this SNP in
2,028 subjects was performed using the TaqMan allelic
discrimination assay. Further details of genotyping and
quality control were available elsewhere [25], whereas in
the Canadian study, SNP rs4977574 was available for
replication and selection for studying the severity of
CAD. This SNP was extracted from the Affymetrix
(Santa Clara, California) 500 K array after GWAS quality
control in 950 subjects. Details of genotyping and quality
control were available elsewhere [27].
Observed genotypes and allele counts for all partici-
pating studies are shown in Additional file 1: Table S4.
Statistical analysis
Statistical analysis within studies
Cardiovascular risk factors (i.e., LDL-cholesterol, HDL-
cholesterol, triglycerides, type 2 diabetes mellitus, hyper-
tension, etc.) obtained at baseline were analyzed using
SPSS (version 17, SPSS, Chicago, Illinois, USA) and
expressed as mean ± SD. Continuous variables were pre-
sented as means ± SD and categorical variables as abso-
lute numbers and proportions (%) with one-way analysis
of variance and chi-squared tests. These tests were also
used to determine difference by genotype for some
9p21.3 variants. Clinical variables deviating from normal
distribution were transformed by taking the natural loga-
rithm of their value. Additional quantifying scores for
severity of CAD, such as the Gensini score [28] (or
modified Gensini [29]), the CAD Prognostic Index (also
called the Duke score) [30], modified Duke [31], Dahlen
score [32], and percent stenosis diameter (defined by the
modified ACC/AHA classification) were assessed with
linear regression. Hardy-Weinberg equilibrium (HWE)
test was carried out for each SNP in the control group.
SNPs with HWE P < 5×10-2 were excluded from the
analysis. For the analysis of genetic data, we used the
GenABEL [33] library of the R package software.
Association analysis
In the Italian study, we conducted association analyses
using linear regression method under an additive genetic
model and executed the analyses in two stages; first, an
association analysis on the 11 SNPs regressed on severity
of CAD (kept as a quantitative variable) using age, sex,
and T2D as covariates; and second, an association ana-
lysis stratified by T2D on the 11 SNPs regressed on se-
verity of CAD using age and sex as covariates after
performing interaction tests between 9p21.3 SNPs and T2D.
In both analytical stages, we supported nominal P value sig-
nificance with empirical P values (i.e., Pemp), which were
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region that included the 11 SNPs tested. Association and
permutation analyses were performed using methods imple-
mented in the GenABEL [33] library of the R software.
In the replication stage: in the German study, associ-
ation analysis was carried out using linear regression
method on severity of CAD under an additive model
and adjusted for age, sex, and T2D. Additionally, associ-
ation in stratified groups by T2D was performed after
testing for interaction between rs1333049 and T2D. As-
sociation was performed using GenABEL package [33].
In the Canadian study, the association analysis was con-
ducted using a logistic regression method. Severity of
CAD in the early-onset CAD group (as defined by the
study design) was dichotomized in two vessel disease
groups: (a) 1-VD versus 2- and 3-VD, and (b) 1- and
2-VD versus 3-VD. Logistic regression was performed
under an additive genetic model, adjusted for age and sex.
Results
Study samples
The characteristics of the patients participating in these
studies are shown in Additional file 1: Table S1. Add-
itionally, baseline characteristics by 9p21.3 genotypes for
severity of CAD are shown in Additional file 1: Table S2.
In the Italian study, 17% of participants had single-vessel
(1VD), 20% had double-vessel (2VD), 16% had triple-
vessel (3VD); the remaining 47% had normal coronary
arteries or a stenosis diameter of < 50%. Furthermore,
64.5% had severity of CAD without T2D and the
remaining percent had severity of CAD with T2D. In the
German study, 83.4% of participants had 1VD, 11% had
2VD, and 5.5% had normal coronary vessels. Herein,
68.5% of participants had severity of CAD without T2DTable 1 Association results derived from linear regression be
as quantitative trait) in the Italian study (N=2,908)
SNP Position Alleles MAF
rs7044859 22,008,781 A/T 0.463
rs10965215 22,019,445 A/G 0.435
rs564398 22,019,547 C/T 0.301
rs7865618 22,021,005 A/G 0.304
rs10116277 22,071,397 G/T 0.390
rs4977574 22,088,574 A/G 0.398
rs2383207 22,105,959 A/G 0.360
rs10738610 22,113,766 A/C 0.386
rs10757278 22,114,477 A/G 0.416
rs1333049 22,115,503 C/G 0.421
rs10811661 22,124,094 C/T 0.206
Boldface allele denotes coded allele; MAF, minor allele frequency; Genetic effects (b
P value denotes statistical nominal significance <0.05; Pemp denotes empirical signif
11 SNPs tested.and the remaining percent had severe CAD with T2D.
In the Canadian study, 30.1% of participants had 1VD,
32.9% had 2VD, and 36.9% had 3VD. In the early onset
CAD, 19.8% of participants had 3VD and 35.6% had
1VD and 2VD. In the late onset CAD, 17.1% of partici-
pants had 3VD and 27.5% had 1VD and 2VD. Within
this study, all participants had severity of CAD without
T2D. Results (Table 1) of the association analysis per-
formed on the 11 SNPs in the 2,908 Italian subjects
showed that two SNPs (rs4977574 and rs2383207) in
high LD (r2 > 0.93) were significantly (Pemp < 0.05) asso-
ciated with severity of CAD after correcting for multiple
testing. Results from testing interaction between 9p21.3
SNPs and T2D are shown in Additional file 1: Table S5.
Results (Table 2) of the association analysis stratified by
T2D revealed that the association between these two SNPs
and severity of CAD continued to be present in subjects
without and with T2D. Additionally, a third SNP
rs10738610 was found to be significantly (Pemp < 1.99×10
-2)
associated with severity of CAD in the subjects with T2D.
This SNP was imputed in 1,212 controls and had an imput-
ation quality of R2 = 0.96. Imputation quality of imputed
SNPs is shown in Additional file 1: Table S3. The linkage
disequilibrium (LD, denoted by r2) among the 11 SNPs is
shown in Additional file 1: Table S7.
Association tests employing other quantifying angio-
graphic scores, including Duke scores, Dahlen scores,
and percent diameter stenosis showed significant evi-
dence of association for rs4977574 and rs2383207 with
severity of CAD, as shown in Additional file 1: Table S6.
Results from the replication stage are shown in
Tables 3 and 4. In the Canadian study, we observed an
association between rs4977574 and severity of CAD in
the early-onset CAD patients without T2D, whichtween 11 9p21.3-variants and severity of disease (defined
Beta s.e. P Pemp
0.015 0.025 5.46E-01 9.87E-01
0.029 0.024 2.31E-01 7.38E-01
0.060 0.026 2.44E-02 1.34E-01
0.063 0.026 1.66E-02 9.44E-02
0.069 0.026 9.14E-03 5.90E-02
0.107 0.025 1.75E-05 4.00E-04
0.100 0.027 1.98E-04 1.50E-03
0.070 0.026 8.36E-03 5.30E-02
0.036 0.025 1.51E-01 5.62E-01
0.041 0.025 9.52E-02 4.01E-01
0.033 0.031 2.88E-01 8.22E-01
etas) adjusted according to severity of CAD ~ age+sex+T2D + SNP. Boldface
icance derived from 10,000 permutations on the 9p21.3 region including the
Table 2 Association results derived from linear regression between 11 9p21.3-variants and severity of disease (defined
as quantitative trait) in the Italian study (N=2,908) stratified by T2D
Without T2D (N=2,343) With T2D (N=565)
SNP Position Alleles MAF Pint Beta s.e. P Pemp Beta s.e. P Pemp
rs7044859 22,008781 A/T 0.463 7.14E-01 0.011 0.028 6.94E-01 9.99E-01 0.024 0.054 6.52E-01 9.99E-01
rs10965215 22,019,445 A/G 0.435 6.82E-01 0.023 0.027 3.93E-01 9.27E-01 0.053 0.052 3.09E-01 8.79E-01
rs564398 22,019,547 C/T 0.301 7.66E-01 0.063 0.030 3.32E-02 1.70E-01 0.032 0.058 5.79E-01 9.96E-01
rs7865618 22,021,005 A/G 0.304 - 0.068 0.029 1.99E-02 1.09E-01 0.030 0.059 6.15E-01 9.98E-01
rs10116277 22,071,397 G/T 0.390 9.83E-02 0.054 0.029 6.01E-02 2.78E-01 0.138 0.067 4.07E-02 2.24E-01
rs4977574 22,088,574 A/G 0.398 9.53E-02 0.087 0.028 1.72E-03 1.17E-02 0.177 0.055 1.21E-03 9.40E-03
rs2383207 22,105,959 A/G 0.360 5.33E-02 0.081 0.029 5.37E-03 3.39E-02 0.198 0.069 4.52E-03 2.91E-02
rs10738610 22,113,766 A/C 0.386 4.28E-02 0.045 0.029 1.14E-01 4.53E-01 0.201 0.067 2.92E-03 1.99E-02
rs10757278 22,114,477 A/G 0.416 2.44E-01 0.019 0.028 5.01E-01 9.77E-01 0.107 0.054 4.61E-02 2.47E-01
rs1333049 22,115,503 C/G 0.421 6.44E-01 0.028 0.028 3.25E-01 8.60E-01 0.099 0.053 6.26E-02 3.16E-01
rs10811661 22,124,094 C/T 0.206 9.85E-01 0.053 0.035 1.26E-01 4.86E-01 0.051 0.068 4.56E-01 9.74E-01
MAF, minor allele frequency; Pint, p-value from interaction tests by T2D as shown in Additional file 1: Table S5; Genetic effects (betas) adjusted according to
model: severity of CAD ~ age+sex+SNP; Boldface allele denotes coded allele; Boldface P value denotes statistical nominal significance <0.05; Pemp denotes empirical
significance derived from 10,000 permutations on the 9p21.3 region including the 11 SNPs tested.
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No genotype data for this SNP was available in the late-
onset group. In the German study, we observed no asso-
ciation between rs1333049 and severity of CAD. In
addition, no association was detected in the stratified
groups by T2D. This finding is in agreement with what
we observed for this SNP.
Discussion
In this study, our aim was to investigate the association be-
tween 9p21.3-variants and the severity of CAD in the pres-
ence and absence of T2D. Results from our analysis showed
that two 9p21.3-variants (rs4977574 and rs2383207) from
the known CAD-associated haplotype, are also associated
with severity of CAD. We also showed that these variants
are associated with severity of CAD in subjects with andTable 3 Replication results; Association results derived
from logistic regression between rs4977574 and severity
of CAD without T2D in Italian (N=2,343) and Canadian
studies (N=950)
EO CAD
OR (95% CI) P
3VD vs. (2VD+1VD)
rs4977574 Italian 1.734 (1.142-2.633) 9.77E-03
Canadian 1.381 (1.124-1.698) 2.14E-03
1VD vs. (2VD+3VD)
rs4977574 Italian 0.721 (0.542-0.958) 2.42E-02
Canadian 0.648 (0.527-0.795) 3.28E-05
Odds ratio (OR) adjusted for age and sex; 05 CI, 95% confidence interval of OR;
Boldface P denotes nominal P value significance <0.05; EO, early-onset CAD;
1VD=1-vessel disease; 2VD=2-vessel disease; 3VD=3-vessel disease.without T2D. Additionally, a third SNP rs10738610, located
inside the same CAD-associated haplotype, was found to be
significantly associated with severity of CAD in subjects with
T2D. The significance of the association for this SNP in the
pooled analysis was slightly above the threshold; however,
this heightened significance was strengthened after
stratification by T2D. Association of rs4977574 with
severity of CAD was confirmed in an independent
study in subjects without T2D. The results of the associ-
ation for SNP rs1333049, which is a well-documented
variant in the association with incidence of CAD and is in
high LD with rs494457 (r2 = 0.89), rs2383207 (r2 = 0.89),
and rs10738610 (r2 = 0.93), showed no association with
severity of CAD in the Italian and German studies. How-
ever, Dandona et al. [34] in the Canadian study demon-
strated that this SNP predicted the severity of coronary
atheromatous burden in patients without T2D.
From our results, we hypothesized that although the
9p21.3 locus does not contain any genes, there are two
different pathological mechanisms harboring the same
haplotype, one that shares a common genetic platform
between molecular mechanisms of CAD and T2D and
the other, an independent one that is linked to the
pathogenesis of CAD alone. Additionally, disagreement
on the associations with severity of CAD of well-
documented 9p21.3 variants associated with CAD var-
iants may be due to various factors, including phenotype
heterogeneity and difference on risk-allele frequencies
among participating studies. The mechanisms of severity
of CAD and T2D in patients with acute coronary syn-
drome (ACS) are complex, and they are not so clear at
present. While many genetic studies, including GWAS,
for CAD and T2D, have identified the 9p21.3 locus as a
Table 4 Replication results; Association results derived from linear regression between rs1333049 and severity of CAD
in the German study (N=2,028)
SNP Position Alleles† MAF Beta s.e. P Pemp
rs1333049 22,115,503 C/G 0.421 0.0119 0.012 3.45E-01 3.44E-01
*Beta adjusted for age and sex; †Boldface allele denotes coded allele; P denotes nominal significance; Pemp denotes empirical significance derived from 10,000
permutations.
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types), there are no functional variants (non-coding variants)
within this region. Therefore, the link between the 9p21.3
locus and the genetic backbones of these two diseases still
remains poorly understood. The 9p21.3 locus lies in proxim-
ity to CDKN2A and CDKN2B. These cyclin-dependent kin-
ase inhibitors (CDKNs) generate several transcript variants
that are involved in diverse biological processes, including
cell proliferation, cellular senescence, cell cycle arrest, induc-
tion of apoptosis, and activation of caspase activity, to name
a few [35,36]. Some of these biological processes are pre-
sumably implicated in the pathogenesis of atherosclerosis as
well as in the other complex phenotypes (i.e., myocardial in-
farction, aortic aneurysm, ischemic stroke, T2D, glioma, and
malignant melanoma). Recent works have speculated that
the pathogenic role of the 9p21.3 locus in atherosclerosis is
influenced by gene expression [37,38] and a transcriptional
and translational control mechanism presumably caused by
cis- and trans-acting elements located in the vicinity of this
region. Yet, no cis- and/or trans-acting mechanisms have
been identified. Other works have elaborated many discus-
sions about the analysis of the 9p21.3 locus and the appro-
priate phenotypic characterization. Thus, genotypic
variability among 9p21.3 variants may be due to wrong phe-
notyping rather than sequence variations influenced by gene
expression. Moreover, it seems that the significance of var-
iants found at this locus is changeable to the phenotype of
interest, its severity, and the presence of combined risk and
environmental factors that correlated with the phenotype.
In our study, we have a well-characterized phenotype for
severity of CAD in subjects with and without T2D. We per-
formed association analyses in three different white popula-
tions of European ancestry, totaling 5,886 subjects. This
enabled us to study the relationship between the 9p21.3
locus, including CAD- and T2D-associated variants, and the
severity of CAD in subjects with and without T2D. More-
over, to reduce phenotype-genotype bias, we used additional
scoring methods for assessing extension of CAD. Then, we
conducted association analyses following two approaches
for assessing the relationship between severity of CAD and
9p21.3-variants. Our finding showed (1) that rs4977574 and
rs2383207 at the 9p21.3 locus are associated with severity of
CAD regardless of T2D status and (2) that rs10738610 is
associated with severity of CAD comorbid with T2D.
This study has limitations: (1) in order to characterize
the 9p21.3 locus more effectively in subjects with severityof CAD and T2D, more variants need to be included in
the analysis and hence tested for association with this
phenotype; (2) observed differences among genetic effects
of 9p21.3 variants across populations may be due to the
quantitative method in which angiographic scores were
calculated in each participating study; (3) lack of availabil-
ity of variants rs2383207 and rs10738610 in replication
stage demands validation of their associations with sever-
ity of CAD in other white population studies with similar
characteristics; (4) phenotype heterogeneity among par-
ticipating studies is likely to be present since each study
was previously designed to answer its own research ques-
tion and had predefined inclusion and exclusion criteria;
(5) In the Italian study, although we cannot discard the
presence of atherosclerosis in the 1,212 controls, prelimin-
ary testing between 9p21.3 variants and incidence of CAD
obtained from follow-up records showed no association
with CAD; (6) lack of availability of 3-vessel disease sub-
jects in the German study may had underestimated the
genetic effect of SNP rs1333049 attained in the replication
stage; and (7) lack of availability of genotype data of SNP
rs497754 in late-onset CAD subjects with severity of CAD
in the Canadian study requires a replication in another co-
hort with similar characteristics as to strengthen the sig-
nificance of this SNP with severity of CAD regardless on
the onset of the disease.
Conclusions
The 9p21.3 locus is significantly associated with severity
of CAD. The number of associations of 9p21.3 variants
with severity of CAD is variable to the presence and ab-
sence of T2D. In a CAD-susceptible region of 115 kb,
there is only one variant associated with the severity of
coronary vessel disease in the presence of type 2 diabetes.
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